Brief: Monte Rosa Therapeutics Outlines Progress Across Portfolio Of Molecular Glue Degraders
09/01/2023 12:50
Jan 9 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS OUTLINES PROGRESS ACROSS PORTFOLIO
OF
MOLECULAR GLUE DEGRADERS AND KEY ANTICIPATED MILESTONES FOR 2023
* MONTE ROSA THERAPEUTICS - DISCLOSURE OF INITIAL DATA FROM
PHASE
1 ARM OF ONGOING PHASE 1/2 CLINICAL TRIAL EVALUATING MRT-2359
EXPECTED IN H2OF 2023
* MONTE ROSA THERAPEUTICS INC - NOMINATION OF MULTIPLE
ADDITIONAL
DEVELOPMENT CANDIDATES ANTICIPATED IN 2023
Source text for Eikon: ID:nGNXFYMfS
Further company coverage: GLUE.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million